Interpretation on the Consensus on Targeted Drug Therapy for Spondyloarthritis
10.12290/xhyxzz.2023-0391
- VernacularTitle:《脊柱关节炎靶向药物治疗专家共识》要点解读
- Author:
Xiaoxi YANG
1
;
Xinping TIAN
1
;
Mengtao LI
1
;
Xiaomei LENG
1
;
Yan ZHAO
1
;
Xiaofeng ZENG
1
Author Information
1. Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
- Publication Type:Journal Article
- Keywords:
spondyloarthritis;
targeted drug therapy;
consensus;
interpretation
- From:
Medical Journal of Peking Union Medical College Hospital
2024;15(1):58-67
- CountryChina
- Language:Chinese
-
Abstract:
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases which predominantly involve spine and/or peripheral joints. SpA can be disabling and seriously affect the quality of life and function of patients. With the increasing clinical use of targeted drug therapy, precise and standardized use becomes the focus. China's first Consensus on Targeted Drug Therapy for Spondyloarthritis was developed by National Clinical Research Center for Dermatologic and Immunologic Diseases using international norms for consensus development. The consensus addresses 13 important clinical questions, ranging from principles, patient eligibility, pre-treatment screening, treatment initiation, drug selection and switch, co-medication, to adverse event monitoring of targeted drug therapy in SpA, and recommends treatment for specific patients, playing a key role in guiding clinical practices.
